Evaluation of the SpinCare™ System in the Treatment of Partial Thickness Burns
NCT ID: NCT02997592
Last Updated: 2022-06-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
44 participants
INTERVENTIONAL
2017-03-20
2021-08-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the SPINNER Device for the Application of Wound Dressing: Treatment of Split Skin Graft Donor Sites
NCT02680106
Study of Silicone Material Inserts To Treat Burn Scars
NCT03159182
Hypertrophic Scarring After Facial Burn
NCT00242970
SNaP Wound Care System Over Skin Cancer Excision Sites and Split Thickness Skin Grafts (STSGs)
NCT01349894
Fractionated Carbon Dioxide Laser and Burn Scar Contractures: Evaluation of Post-Treatment Scar Function and Appearance
NCT02115646
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The objective of this study is to evaluate the performance, safety and efficacy of the SpinCare System in the treatment of superficial to intermediate partial thickness burns.
The study included 3 sites. Adult patients with superficial to intermediate partial thickness burns (second degree superficial to intermediate) of up to 10% TBSA (Total Body Surface Area); with an independent burn of up to 5% TBSA.
A prospective single arm, safety and efficacy, open labeled, multi-center study for the treatment of partial thickness burn wounds not considered for surgery using the SpinCare System.
44 patients enrolled in the study.
Endpoints:
* Wound healing and re-epithelialization on day 21.
* The burn will be considered healed when at least 95% of the total area is re-epithelialized and no scabs exist.
* Ease of use
* At postoperative days 7, 14, 21
* Dermal safety assessed by Draize Score
* Visual estimate of wound healing and re-epithelialization
* Pain
* Infection
* Itching
* Itching and scar quality at 3 and 6 months
* Itching and scar quality at 12 months (optional)
* Device related adverse events
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SpinCare
Patients with partial thickness burns treated with the SpinCare System
SpinCare
The burn wound is treated using the SpinCare Systen
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SpinCare
The burn wound is treated using the SpinCare Systen
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient has partial thickness burn wounds (second degree superficial to intermediate) of up to 10% TBSA; of which the target wound for treatment is of up to 5% TBSA or up to 300cm2.
* Presenting at the emergency room within the first 24-48 hours post-injury.
* Patient's wound is defined as a partial thickness burn for conservative treatment (superficial to intermediate second degree).
* Patient underwent cleansing/debridement of initial burn before applying the dressing
* The patient is able and willing to comply with study procedures and give written informed consent prior to enrollment in the study
Exclusion Criteria
* Any known sensitivity to components/products used in this study
* Any active, uncontrolled, progressive or untreated malignancy
* Use of penicillamine, corticosteroid or immunosuppressive medication within two months prior to enrollment or who is likely to be prescribed these medications or any other medications known to adversely affect wound healing during study participation
* Major uncontrolled systemic disorders such as hepatic, renal, neurologic, or endocrinologic disorders
* Major dermatological disorders such as: psoriasis, pemphigus, Steven Johnson, etc.
* Patients with burns larger than 10% TBSA
* Patients with burns up to 10% TBSA but no target wound of up to 5% TBSA or up to 300cm2
* Patients suffering from electrical or chemical burns.
* Patients suffering from frostbites.
* Patients suffering from burn wounds that are third degree or full thickness.
* Patients suffering from burn wounds in the head, neck or genital areas
* Female patients who are pregnant or nursing
* Psychiatric patient.
* Soldiers
* Participation in another clinical trial within 30 days prior to the Screening Visit
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nanomedic Technologies Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Moti Harats, Dr
Role: PRINCIPAL_INVESTIGATOR
Sheba Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rambam Medical Center
Haifa, , Israel
Burn Unit, Sheba Medical Center
Ramat Gan, , Israel
Sourasky Medical Center
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIP0009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.